Medicine profile
Mazdutide
Dual GLP-1 and glucagon receptor agonist developed by Innovent in China under licence from Lilly; regional stages differ and a programme in China is not a UK, US or EU status.
- Generic name
- Mazdutide
- Also known as
- IBI362, LY3305677
- Sponsor and licensing
- Innovent Biologics (licensee (China)), Eli Lilly (originator)
- Mechanism
- GLP-1 and glucagon receptor agonist
- Molecular type
- Peptide (mechanism and molecular type are recorded separately: GLP-1 activity does not make a medicine a peptide)
Brands, routes and formulations
Mazdutide (no brand yet)
subcutaneous 路 once-weekly injection
No verified approval recorded for this product.
Regulatory status by jurisdiction
Authorisation, launch and funded access are three different things and are shown separately. "Not recorded" means GLPInfo has not verified an event, not that nothing has happened.
| United States (FDA) | United Kingdom (MHRA) | European Union (EMA / EC) | |
|---|---|---|---|
| Regulatory authorisation | Not recorded | Not recorded | Not recorded |
| Commercial launch | Not recorded | Not recorded | Not recorded |
| Funded access | Not recorded | Not recorded | Not recorded |
Development timeline
Mazdutide
No verified events recorded yet.
Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Select a marker to open its record in the pipeline view, which has the detail panel and the accessible list.
Next milestone and forecast rationale
No forecast is published for Mazdutide. One appears only when there is a responsible range with assumptions and sources.
Trial evidence
| Trial | Phase | Population | Duration | Results |
|---|---|---|---|---|
| GLORY-1Innovent Biologics (licensee); originator Eli Lilly 路 subcutaneous, once weekly | 3 (Innovent, China) | 610 adults in China with obesity or overweight and at least one obesity-related condition | 48 weeks | On file from the research workbook; withheld until the primary publication or registry record is attached. |
GLPInfo does not rank unrelated trials against each other or quote "weight loss per week": populations, durations and methods differ and weight change is not linear. Results appear here per trial and dose arm, with comparator, endpoint and source, once cited.
Known limitations and official labels
This profile is assembled from the regulatory records and sponsor statements GLPInfo has verified; it is not a complete review of Mazdutide. The current official label in each jurisdiction is the authority on indications, populations and safety.
Review date and correction history
Records last checked 13 Sep 2026. No corrections have been made to the records on this profile; every record is at version 1. Report a correction.
Related news
No news articles yet for Mazdutide.